Blanket Purchase Agreement V797D30296-VA797P14A0002

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency under the Department of Veterans Affairs, to Astellas Pharma US, Inc., a foreign-owned pharmaceutical manufacturer. The BPA, valued at $296,500, is for the procurement of the oncology drugs XTANDI and XOSPATA, as well as the drug ZYLOY. This BPA was established against Astellas' existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs, which has a total potential value...

The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY...

The Defense Health Agency (DHA) awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The BPA has a ceiling value of $1,000,000 and a period of performance through January 31, 2028. The contract is not set aside for small businesses. Under this BPA, the DHA...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the Department of Veterans Affairs (VA) to Daiichi Sankyo, Inc., a pharmaceutical manufacturer. The single-award BPA, valued at $80,206.95, provides a mechanism for VA healthcare facilities nationwide to efficiently procure the specialty drug pexidartinib (marketed as TURALIO) in various dosage forms. Pexidartinib is used to treat tenosynovial giant cell tumor, a rare disease, in eligible veteran patients....

The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Urogen Pharma Inc. The BPA has a potential value of $1.5 million and expires on February 3, 2021. It was established on October 2, 2020 to procure Jelmyto, a treatment for low-grade upper tract urothelial cancer. As the sole awardee, Urogen Pharma will provide its product Jelmyto to the VA National Acquisition Center through this BPA. Jelmyto is an FDA-approved medication for the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a component of the U.S. Department of Veterans Affairs (VA), to Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.). The $15,000,000 single-award BPA has a period of performance from September 2024 through September 2025 and is for the provision of the oncology drugs BALVERSA (erdafitinib) and CARVYKTI (ciltacabtagene autoleucel). Janssen Biotech is a major pharmaceutical manufacturer that...

This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA), Network Contracting Office 9 (NCO 9), to Advanced Accelerator Applications USA Inc., a foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $49.2 million BPA is for the procurement of PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), a radiopharmaceutical used in cancer treatment and diagnostic imaging. The BPA is established under the Pharmaceuticals...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 4 awarded a single award indefinite delivery contract to Cardinal Health 414, LLC for the delivery of XOFIGO. A firm fixed price delivery order was issued against the contract for $317,697.83 to provide XOFIGO injection for delivery to facilities in Philadelphia, Pennsylvania by January 10, 2022. No set aside provision was specified for this procurement. The originating special notice...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center of the U.S. Department of Veterans Affairs (VA) to Urogen Pharma Inc., a pharmaceutical company specializing in the drug JELMYTO. The single-award BPA, valued at up to $2.5 million, was made under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and is valid through February 2026. The purpose of this BPA is to provide the VA with a streamlined procurement vehicle to order JELMYTO, a drug used to...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Advanced Accelerator Applications USA Inc., a large, foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $23.4 million single-award BPA is under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has an ultimate completion date of February 3, 2025. The BPA is for the procurement of LOCAMETZ and NETSPOT, two...